EUCTR2009-012950-19-IT进行中（未招募）不适用
Multicentre study to optimize therapy of B-ALL and high grade non-Hodgkin Lymphoma in Adults - ND
ILG (Northern Italy Leukemia Group)0 个研究点开始时间: 2009年11月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Burkitt`s leukemia or Burkitt`s lymphoma Age > 15 years Written informed consent
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Serious secondary diseases, including psychiatric conditions, under which the required therapy compliance is not to be expected Secondary lymphoma following prior chemotherapy/radiotherapy or active second malignancy Known severe allergy to foreign proteins Pre-treatment other than 1 cycle CHOP or similar; < 1 week of another chemotherapy. Pregnancy or nursing Participation in other studies that interfere with study therapy
研究者
相似试验
进行中（未招募）
不适用
Multizentrische Therapieoptimierungsstudie AML-BFM 2004 zur Behandlung der akuten myeloischen Leukämien bei Kindern und JugendlichenMulticentric therapy optimizing study AML-BFM 2004 for the treatment of acute myeloic leukaemias for children and juveniles - AML-BFM 2004For acute myeloic leukaemia in children and juveniles improvment of treatment with new medications should be investigated:1. Cladribine: originally licenced for hairy cell leukamia has shown good success in the USA in the treatment of aml in children, esp. for high-risk-patients2. Daunoxome: liposomal form of Idarubicin (already in use for aml treatment, but with a dose rate depending risk of heart degradation). It should be proved, if Daunoxome could be administered with less side effectsMedDRA version: 8.1Level: LLTClassification code 10001941Term: AMEUCTR2006-004710-41-ATSt. Anna Kinderkrebsforschung550
进行中（未招募）
不适用
Multicentre study of optimization of therapy in mature B-cell acute lymphoblastic leukemia and Burkitt's lymphoma in adults (over 15 years) - BURKIMABEUCTR2005-001067-64-ESPETHEMA Foundation20
已完成
3 期
Established Status Epilepticus Treatment TrialBenzodiazepine Refractory Status EpilepticusNCT01960075University of Virginia478
招募中
不适用
Multicenter trial of effectiveness and safety of bronchial thermoplasty in bronchial asthmaBronchial asthmaJPRN-UMIN000025244Japanese Red Cross Medical Center40
未知
3 期
Clinical study of combination therapy of HLBI plus SMP-275 ribavirin in patients with chronic hepatitis CJPRN-jRCT2080220092Dainippon Sumitomo Pharma Co., Ltd.